Clinical Trials on Lipid Metabolism Disorder in Germany

Total 8039 results

Bristol-Myers Squibb

Terminated

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Atherosclerosis | Hypercholesterolemia

Germany
Solvay Pharmaceuticals

Terminated

Effect of Omacor on Triglycerides in HIV Infected Subjects

Hyper-Triglyceridemia

Germany, United Kingdom
Novartis

Completed

A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Hypercholesterolemia | Essential Hypertension

Switzerland, Germany
University Hospital Muenster
Amicus Therapeutics

Completed

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

Fabry Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

Fabry Disease

Germany
Charite University, Berlin, Germany

Withdrawn

Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a) (ELAILa)

Hyperlipoproteinemia(a) | Progressive Cardiovascular Disease

Germany
Sanofi

Terminated

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States, France, Canada, Poland, Russian Federation, Germany, Netherlands, Spain, Sweden, Belgium, Czech Republic, Denmark, Hungary, Israel, Norway, Australia
Novartis Pharmaceuticals

Active, not recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Hyperlipoproteinemia(a)

Germany
Amgen

Completed

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Hypercholesterolemia

France, Germany, United States, Czechia, Italy, Australia, Spain, United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Atorvastatin Three Year Pediatric Study

Familial Hypercholesterolemia

United States, Spain, Turkey, Canada, Belgium, Germany, Greece, Hungary, Italy, Norway, Poland, Puerto Rico, Russian Federation, Slovakia, Switzerland
Greenovation Biotech GmbH
FGK Clinical Research GmbH

Completed

Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease

Fabry Disease

Germany
Shire

Completed

Home Therapy With VPRIV in Gaucher's Disease

Gaucher Disease

Austria, Germany
Amryt Pharma

Active, not recruiting

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Homozygous Familial Hypercholesterolaemia (HoFH)

Germany, Israel, Italy, Saudi Arabia, Spain, Tunisia
Esperion Therapeutics, Inc.

Recruiting

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Hypercholesterolemia

United States, Spain, Denmark, Canada, Netherlands, Germany
Radboud University Medical Center
AstraZeneca; Abbott

Completed

Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients

HIV Infections | Hyperlipidemia

Germany, Netherlands
Takeda

Active, not recruiting

Early Detection of Fabry Disease

Fabry Disease

Germany
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Wolman Disease (BioWolman) (BioWolman)

Cholesterol Ester Storage Disease | Acid Lipase Deficiency | Acid Cholesteryl Ester Hydrolase Deficiency, Wolman Type

Germany, India, Sri Lanka
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Technische Universität Dresden
Kaneka Pharma Europe N.V.

Recruiting

Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes (MultiSELECt)

Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia

Germany
Ludwig-Maximilians - University of Munich

Completed

Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis (MICA)

Atherosclerosis | LDL-hypercholesterolemia

Germany
Johannes Gutenberg University Mainz

Unknown

Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. (MPSORA)

Mucopolysaccharidosis | Fabry Disease

Germany
University Hospital Freiburg
Essex Pharma GmbH

Completed

Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes (EZE)

Hypercholesterolemia | Diabetes Mellitus Type 2

Germany
Freeline Therapeutics

Completed

A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

Lysosomal Storage Diseases | Fabry Disease

Germany, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Heterozygous Familial Hypercholesterolemia

United States, Germany
Analyze & Realize

Unknown

Evaluation of the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile

Blood Pressure | Endothelial Function | Lipid Metabolism

Germany
CENTOGENE GmbH Rostock

Withdrawn

Fabry and Cardiomyopathy (FaCard) (FaCard)

Stroke, Acute | Cerebrovascular Accident | Cerebral Stroke

Germany
German Institute of Human Nutrition
California Walnut Commission; German Center for Diabetes Research; Institute...

Unknown

POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes (POLYPHEM)

Hypertension | Obesity | Metabolic Syndrome | Type 2 Diabetes | Dyslipidemia | NAFLD

Germany
Sanofi

Terminated

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Obesity | Dyslipidemias

Germany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
Abbott

Completed

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Dyslipidemia

Argentina, Czech Republic, Germany, Mexico, Poland, Romania, Russian Federation
Wuerzburg University Hospital
Charite University, Berlin, Germany; University Hospital Muenster; Health Care...

Recruiting

MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study (MALTA-FABRY)

Quality of Life | Adherence, Medication | Fabry Disease | Rare Diseases

Germany
Sanofi

Completed

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS)

Atherosclerotic Cardiovascular Disease | Primary Hypercholesterolaemia and Mixed Dyslipidaemia

Germany
AstraZeneca

Completed

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

Hypercholesteremia

United States, France, Norway, Netherlands, Belgium, Germany, Finland, Czech Republic
LIB Therapeutics LLC
Medpace, Inc.

Active, not recruiting

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (LIBerate-VI)

Hypercholesterolemia | Atherosclerotic Ischemic Disease

Spain, Germany, France, Norway, United Kingdom
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Prevail Therapeutics
Eli Lilly and Company

Recruiting

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Gaucher Disease | Gaucher Disease, Type 1

United States, Spain, Germany
Fresenius Medical Care Deutschland GmbH

Completed

Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter (LINET)

Hypercholesterolemia, Familial | LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA

Germany
Takeda

Completed

Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Hypercholesterolemia

Poland, United Kingdom, Germany, South Africa, Finland, Estonia, Czech Republic
BioMarin Pharmaceutical

Completed

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 Disorder

United States, Germany, Italy, United Kingdom
BioMarin Pharmaceutical

Completed

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 Disorder

United States, Germany, Italy, United Kingdom
Hannover Medical School
Hector-Stiftung

Completed

Role of the Autonomic Nervous System in HIV-Lipodystrophy

HIV Infections | Lipodystrophy-Syndrome

Germany
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. (V-Mono)

Hypercholesterolemia

United States, Germany, Hungary, Colombia, Mexico
Solvay Pharmaceuticals

Completed

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Hyperlipidemia

Bulgaria, Czech Republic, Germany, Slovakia, Ukraine
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database

Batten Disease | Neuronal Ceroid Lipofuscinosis | CLN1 Disease | CLN2 Disease | CLN3 Disease | CLN4 Disease | CLN5 Disease | CLN6 Disease | CLN7 Disease | CLN8 Disease | CLN10 Disease | CLN11 Disease | CLN12 Disease | CLN13 Disease | CLN14 Disease

Germany
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada, France, Germany, United Kingdom, Netherlands
Kowa Research Europe

Completed

Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

Dyslipidemias | Hypercholesterolemia

Denmark, Israel, Germany, Netherlands, United Kingdom
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
Takeda

Completed

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Dyslipidemia

United States, Germany, Argentina, Mexico, Poland, South Africa, Chile, Netherlands, Peru, Estonia, Russian Federation, Czech Republic, Hungary, Lithuania, Latvia, Slovakia, United Kingdom
BioMarin Pharmaceutical

Completed

A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease

United States, Italy, Germany, United Kingdom

Clinical Trials on Lipid Metabolism Disorder in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations